AMETEK Q3 2025 Earnings Call Summary

1Key Financial Results and Metrics

Sales: Record $1.89 billion, up 11% from Q3 2024.

Organic Sales: Increased by 4%, with acquisitions contributing 6% and foreign currency translation adding 1%.

Orders: Record $1.97 billion, up 13%, with organic orders up 7%, leading to a backlog of $3.54 billion.

Operating Income: $496 million, an 11% increase year-over-year.

EBITDA: Record $592 million, with margins at 31.3%.

Earnings per Share: $1.89, up 14% from Q3 2024.

Free Cash Flow: $420 million, with a conversion rate of 113% of net income.

Debt: Total debt increased to $2.5 billion due to the acquisition of FARO Technologies.

2Strategic Updates and Business Highlights

Business Performance:

Electronic Instruments Group (EIG) sales were $1.25 billion, up 10%; organic sales were flat.

Electromechanical Group (EMG) sales reached $646 million, up 13% with organic growth of 12%.

Acquisitions: Integration of recent acquisitions (FARO, Virtek, Kern, Paragon) is progressing well, contributing positively to results.

Investment in Growth: AMETEK plans to invest an additional $90 million in organic growth initiatives for R&D and digital marketing in 2025.

Product Innovations: New AI-powered products launched in the Virtek Vision and NSI-MI Technologies businesses, enhancing capabilities in aerospace and industrial applications.

3Forward Guidance and Outlook

Earnings Guidance: Increased to $7.32 to $7.37 per diluted share for the full year, representing a 7% to 8% increase from 2024.

Q4 Expectations: Anticipated sales growth of approximately 10%, with earnings projected between $1.90 and $1.95 per share, reflecting a 2% to 4% increase year-over-year.

4Bad News, Challenges, or Points of Concern

Macroeconomic Uncertainty: Ongoing trade conflicts are causing delays in decision-making and demand timing, particularly affecting the Process markets.

China Market: Experiencing softness due to tariff negotiations impacting pricing and customer decisions.

Process Industries: Organic sales are expected to remain flat to down low single digits for the year, with concerns about delayed project activity.

5Notable Q&A Insights

Customer Confidence: AMETEK is seeing improved customer confidence and order momentum, particularly in Automation and Engineered Solutions.

Paragon Performance: Paragon Medical is performing well, with double-digit order growth and margins aligning with AMETEK's standards, despite initial concerns post-acquisition.

Market Dynamics: The Automation market is recovering, with discrete automation showing strength, while the overall industrial economy is expected to improve.

M&A Pipeline: AMETEK maintains a strong acquisition pipeline and is actively pursuing strategic opportunities, with a disciplined approach to capital deployment. Overall, AMETEK reported a strong quarter with record financial results, positive strategic developments, and an optimistic outlook, despite facing some macroeconomic challenges and uncertainties.